Abstract:The human microbiome is a predictor of clinical outcome in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT). Besides bacteria, fungi and viruses as well as intestinal microbiota-derived metabolites are involved. However, it is still unclear how dynamic shifts in these three kingdoms contribute to the production of intestinal metabolites, how metabolites are impacted by graft-versus-host disease (GvHD) or antibiotics and whether they are associated with clinical outcome. We report the two-year follow-up of a prospective, observational, longitudinal cohort of allo-SCT patients (n=78) at two German transplantation centers that combined three-kingdom (bacteria, fungi, viruses) analysis of intestinal microbial communities with targeted metabolomics ( Figure 1). Using Multi-omics factor analysis (MOFA), we uncovered a functional microbiome signature of bacteria from the Lachnospiraceae and Oscillospiraceae families and their associated bacteriophages, which correlated with the production of immuno-modulatory metabolites (IMMs) including short-chain fatty acids (SCFAs), branched-chain fatty acids (BCFA), metabolites associated with induction of type-I IFN signaling (IIMs) and immuno-modulatory secondary bile acids ( Figure 2). We established an Immuno-modulatory Metabolite Risk Index (IMM-RI) consisting of five index IMMs, which was associated with improved survival, less transplant-related mortality and reduced relapse rate. Onset of gastrointestinal GvHD and exposure to antibiotics significantly impacted intestinal levels of protective IMMs. Using whole shotgun metagenomic sequencing, we observed that in IMM-RI low-risk patients, sustained production of protective IMMs was associated with a high abundance of microbial SCFA biosynthesis pathways, specifically butyric acid via butyryl-CoA:acetate CoA-transferase (BCoAT). Through genome assembly from viral metagenomic sequencing data, we detected two distinct bacteriophages which encoded BCoAT as an auxiliary metabolic gene. They were more abundant in IMM-RI low-risk patients and positively correlated with intestinal butyric acid levels, suggesting that these bacteriophages may modulate bacterial metabolite biosynthesis. Our study identifies a specific microbiome signature associated with protective IMMs that could improve fecal microbiota transplantation (FMT) donor selection and provides a rationale for the development of engineered metabolite-producing consortia and defined metabolite combination drugs as novel microbiome-based therapies for cancer patients.

Personalized engraftment risk prediction and probiotic therapy assessment in the human gut

Metabolic model-based ecological modeling for probiotic design

Microbial community-scale metabolic modelling predicts personalized short-chain fatty acid production profiles in the human gut

Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features

Microbial community-scale metabolic modeling predicts personalized short chain fatty acid production profiles in the human gut

Identification of key taxa that favor intestinal colonization of Clostridium difficile in an adult Chinese population

Systems-ecology designed bacterial consortium protects from severe Clostridioides difficile infection

Metabolic model predictions enable targeted microbiome manipulation through precision prebiotics

Exploration of Potential Gut Microbiota-Derived Biomarkers to Predict the Success of Fecal Microbiota Transplantation in Ulcerative Colitis: A Prospective Cohort in Korea

Higher alpha diversity and Lactobacillus blooms are associated with better engraftment after Fecal Microbiota Transplant in Inflammatory Bowel Disease

Optimization of probiotic therapeutics using machine learning in an artificial human gastrointestinal tract

The interplay of gut microbiota between donors and recipients determines the efficacy of fecal microbiota transplantation

Gut Colonization Mechanisms of <i>Lactobacillus</i> and <i>Bifidobacterium</i>: An Argument for Personalized Designs

Rational Design of Live Biotherapeutic Products for the Prevention of Infection

In Silico Analysis of Changes in Predicted Metabolic Capabilities of Intestinal Microbiota after Fecal Microbial Transplantation for Treatment of Recurrent Clostridioides difficile Infection

A computational method to dissect colonization resistance of the gut microbiota against pathogens

From metagenomic data to personalized computational microbiotas: Predicting dietary supplements for Crohn's disease

A microbial community cultured in gradient hydrogel for investigating gut microbiome‐drug interaction and guiding therapeutic decisions

Bacterial and Bacteriophage Consortia Are Associated with Protective Intestinal Immuno-Modulatory Metabolites in Allogeneic Stem Cell Transplantation Patients

Novel Microbial Engraftment Trajectories following Microbiota Transplantation Therapy in Ulcerative Colitis

Detecting microbial engraftment after FMT: sorting signals from noise using placebo sequencing and culture-enriched metagenomics